1. |
Qaseem A, Yost J, Forciea MA, et al. The development of living, rapid practice points: summary of methods from the scientific medical policy committee of the American college of physicians. Ann Intern Med, 2021, 174(8): 1126-1132.
|
2. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(2): 229-236.
|
3. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(5): 673-679.
|
4. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Update alert 2: should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(12): W116-W117.
|
5. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2, update alert 3). Ann Intern Med, 2022, 175(5): W55-W57.
|
6. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(6): 828-835.
|
7. |
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2022, 175(4): 556-565.
|
8. |
陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2023, 176(1): 92-104.
|
9. |
GIN. WHO and rapid advice guidelines: history and future directions.
|
10. |
World Health Organization. WHO handbook for guideline development (2nd edition).
|
11. |
El Mikati IK, Khabsa J, Harb T, et al. A framework for the development of living practice guidelines in health care. Ann Intern Med, 2022, 175(8): 1154-1160.
|
12. |
Alper BS, Haynes RB. EBHC pyramid 5. 0 for accessing preappraised evidence and guidance. Evid Based Med, 2016, 21(4): 123-125.
|
13. |
Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022).
|
14. |
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011, 64(4): 383-394.
|
15. |
Balshem H, Helfanda M, Schunemann HG, 等. GRADE指南: Ⅲ. 证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
|
16. |
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
|
17. |
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
|
18. |
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
|
19. |
杨楠, 赵巍, 潘旸, 等. 针对临床实践指南科学性、透明性和适用性的评级工具研发. 中华医学杂志, 2022, 102(30): 2329-2337.
|
20. |
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. ascertaining the minimal clinically important difference. Control Clin Trials, 1989, 10(4): 407-415.
|
21. |
Scottish Intercollegiate Guidelines Network. A handbook for patient and careers representatives.
|